The Scientific Center for Translational Medicine at Sirius University revealed the preliminary results of their preclinical trials for a revolutionary multi-epitope mRNA vaccine against tuberculosis. The press service of the educational center reports that, during the research conducted on rodents, the drug demonstrated remarkable effectiveness.
The BCG vaccine is currently the sole approved vaccine for the prevention of TB. The main drawback is that it fails to offer comprehensive protection against pulmonary tuberculosis in adults. The booster use of BCG vaccine is not recommended by the WHO, because the risk of side effects outweighs the possible benefits”, said the director of the Scientific Center Roman Ivanov. He also added that the development of “Sirius” will be more effective than BCG.
The development of a new TB vaccine was announced in the spring of 2023. Currently, the development is undergoing preclinical trials, and then an application for clinical trials will be submitted.
